Rosemary Delaney
About
In The Last Decade
Rosemary Delaney
12 papers receiving 685 citations
Hit Papers
Peers
Comparison fields: 5 of 55
- Oncology 594
- Pulmonary and Respiratory Medicine 324
- Radiology, Nuclear Medicine and Imaging 198
- Cancer Research 135
- Molecular Biology 89
Countries citing papers authored by Rosemary Delaney
This map shows the geographic impact of Rosemary Delaney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rosemary Delaney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rosemary Delaney more than expected).
Fields of papers citing papers by Rosemary Delaney
This network shows the impact of papers produced by Rosemary Delaney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rosemary Delaney. The network helps show where Rosemary Delaney may publish in the future.
Co-authorship network of co-authors of Rosemary Delaney
This figure shows the co-authorship network connecting the top 25 collaborators of Rosemary Delaney. A scholar is included among the top collaborators of Rosemary Delaney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rosemary Delaney. Rosemary Delaney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 19 | |
| 2 | Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial breakdown → | 210 |
| 3 | 1 | |
| 4 | 26 | |
| 5 | Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer breakdown → | 176 |
| 6 | 37 | |
| 7 | 19 | |
| 8 | 81 | |
| 9 | 18 | |
| 10 | 89 | |
| 11 | 13 | |
| 12 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.